title: [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
abstract: BACKGROUND
  The glucagon-like peptide-1 (GLP-1) mimetics are an established therapeutic option for patients with type 2 diabetes. However, the properties of the GLP-1 mimetics go beyond the strict metabolic control of the patients with diabetes. The neuroprotective effects of GLP-1 have been shown in recent studies opening new areas of research in neurodegenerative diseases such as Alzheimer's disease (AD), among others. AIM. Systematic review including experimental studies and human clinical trials demonstrating the neuroprotective properties of GLP-1 mimetics in AD.
  
  
  METHODS
  The experimental studies that have been conducted in rodent models of AD have demonstrated the neuroprotective properties of GLP-1 in the central nervous system reducing beta-amyloid plaques, the oxidative stress and the inflammatory brain response. Clinical trials in patients with cognitive impairment and AD testing the effects of GLP-1 analogs have recently started.
  
  
  CONCLUSIONS
  The GLP-1 analogs have neuroprotective properties. Considering that type 2 diabetes is a risk factor for cognitive impairment and dementia, the benefits of GLP-1 mimetics on cognition must be considered. Likewise, the GLP-1 mimetics represent a promising treatment for neurodegenerative diseases such as AD.
authors.affiliation: Departamento de Medicina; Facultad de Medicina; Universidad de Málaga; Centro de Investigaciones Médico-Sanitarias, CIMES.
authors.forename: Natalia
authors.initials: N
authors.lastname: García-Casares
authors.affiliation: Unidad de Gestión Clínica de Endocrinología.
authors.forename: Juan Antonio
authors.initials: JA
authors.lastname: García-Arnés
authors.affiliation: Departmento de Medicina; Facultad de Medicina; Universidad de Málaga; Unidad de Gestión Clínica de Medicina Interna.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Gómez-Huelgas
authors.affiliation: Departamento de Medicina; Facultad de Medicine; Universidad de Málaga; Centro de Investigaciones Médico-Sanitarias, CIMES; Hospital Universitario Virgen de la Victoria, Málaga, España.
authors.forename: Pedro
authors.initials: P
authors.lastname: Valdivielso-Felices
authors.affiliation: Departamento de Medicinna; Facultad de Medicina; Universidad de Málaga; Unidad de Gestión Clínica de Endocrinología.
authors.forename: Carlota
authors.initials: C
authors.lastname: García-Arias
authors.affiliation: Departmento de Medicina; Facultad de Medicina; Universidad de Málaga; Centro de Investigaciones Médico-Sanitarias, CIMES; Fundación General de la Universidad de Malaga.
authors.forename: Pedro
authors.initials: P
authors.lastname: González-Santos
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D001812:Blood-Brain Barrier; D001923:Brain Chemistry; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000523:psychology; D004353:Drug Evaluation, Preclinical; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000819:agonists* / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D054795:Incretins / Q000502:physiology; D007333:Insulin Resistance; D000069450:Liraglutide; D008959:Models, Neurological; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D018027:Receptors, Glucagon / Q000187:drug effects / Q000502:physiology; D012307:Risk Factors; D014688:Venoms / Q000494:pharmacology / Q000627:therapeutic use; D000067758:Glucagon-Like Peptide-2 Receptor
chemical_list: D000077270:Exenatide; D052216:Glucagon-Like Peptide 1; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D054795:Incretins; D000069450:Liraglutide; D018696:Neuroprotective Agents; D010455:Peptides; D018027:Receptors, Glucagon; D014688:Venoms; C000593833:GLP1R protein, human; C479460:lixisenatide; D000067758:Glucagon-Like Peptide-2 Receptor